Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis

Cancer Research

Volumn 64, Issue 3, 2004, Pages 1008-1015

  Kessler, Ofra ^a   Shraga Heled, Niva ^a   Lange, Tali ^a   Gutmann Raviv, Noga ^a   Sabo, Edmond ^b   Baruch, Limor ^a   Machluf, Marcelle ^a   Neufeld, Gera ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROPILIN 1; NEUROPILIN 1 RECEPTOR; NEUROPILIN 2; NEUROPILIN 2 RECEPTOR; PLEXIN A; PROTEIN; SEMAPHORIN; SEMAPHORIN 3A; SEMAPHORIN 3F; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; SEMAPHORINS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0842304286     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3090     Document Type: Article

References (52)

1. Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y. T., Giger, R. J., and Ginty, D. D. Neuropilin is a semaphorin III receptor. Cell, 90: 753-762, 1997.
2. He, Z., and Tessier-Lavigne, M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell, 90: 739-751, 1997.
3. Roche, J., Boldog, F., Robinson, M., Robinson, L., Varella-Garcia, M., Swanton, M., Waggoner, B., Fishel, R., Franklin, W., Gemmill, R., and Drabkin, H. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene, 12: 1289-1297, 1996.
4. Xiang, R. H., Hensel, C. H., Garcia, D. K., Carlson, H. C., Kok, K., Daly, M. C., Kerbacher, K., van den, B. A., Veldhuis, P., Buys, C. H., and Naylor, S. L. Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics, 32: 39-48, 1996.
5. Xiang, R., Davalos, A. R., Hensel, C. H., Zhou, X. J., Tse, C., and Naylor, S. L. Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res., 62: 2637-2643, 2002.
6. Chen, H., Chedotal, A., He, Z., Goodman, C. S., and Tessier-Lavigne, M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron, 19: 547-559, 1997.
7. Takahashi, T., and Strittmatter, S. M. PlexinA1 Autoinhibition by the Plexin Sema Domain. Neuron, 29: 429-439, 2001.
8. Giger, R. J., Urquhart, E. R., Gillespie, S. K., Levengood, D. V., Ginty, D. D., and Kolodkin, A. L. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron, 21: 1079-1092, 1998.
9. Neufeld, G., Cohen, T., Shraga, N., Lange, T., Kessler, O., and Herzog, Y. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med., 12: 13-19, 2002.
10. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., and Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform specific receptor for vascular endothelial growth factor. Cell, 92: 735-745, 1998.
11. Gluzman-Poltorak, Z., Cohen, T., Herzog, Y., and Neufeld, G. Neuropilin-2 and Neuropilin-1 are receptors for 165-amino acid long form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145 amino acid form of VEGF. J. Biol. Chem., 275: 18040-18045, 2000.
12. Gluzman-Poltorak, Z., Cohen, T., Shibuya, M., and Neufeld, G. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J. Biol. Chem., 276: 18688-18694, 2001.
13. Migdal, M., Huppertz, B., Tessler, S., Comforti, A., Shibuya, M., Reich, R., Baumann, H., and Neufeld, G. Neuropilin-1 is a placenta growth factor-2 receptor. J. Biol. Chem., 273: 22272-22278, 1998.
14. Makinen, T., Olofsson, B., Karpanen, T., Hellman, U., Soker, S., Klagsbrun, M., Eriksson, U., and Alitalo, K. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J. Biol. Chem., 274: 21217-21222, 1999.
15. Karkkainen, M. J., Saaristo, A., Jussila, L., Karila, K. A., Lawrence, E. C., Pajusola, K., Bueler, H., Eichmann, A., Kauppinen, R., Kettunen, M. I., Yla-Herttuala, S., Finegold, D. N., Ferrell, R. E., and Alitalo, K. A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. USA, 98: 12677-12682, 2001.
16. Herzog, Y., Kalcheim, C., Kahane, N., Reshef, R., and Neufeld, G. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech. Dev., 109: 115-119, 2001.
17. Moyon, D., Pardanaud, L., Yuan, L., Breant, C., and Eichmann, A. Plasticity of endothelial cells during arterial-venous differentiation in the avian embryo. Development, 128: 3359-3370, 2001.
18. Yuan, L., Moyon, D., Pardanaud, L., Breant, C., Karkkainen, M. J., Alitalo, K., and Eichmann, A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development, 129: 4797-4806, 2002.
19. Kawasaki, T., Kitsukawa, T., Bekku, Y., Matsuda, Y., Sanbo, M., Yagi, T., and Fujisawa, H. A requirement for neuropilin-1 in embryonic vessel formation. Development, 126: 4895-4902, 1999.
20. Takashima, S., Kitakaze, M., Asakura, M., Asanuma, H., Sanada, S., Tashiro, F., Niwa, H., Miyazaki, J. J., Hirota, S., Kitamura, Y., Kitsukawa, T., Fujisawa, H., Klagsbrun, M., and Hori, M. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc. Natl. Acad. Sci. USA, 99: 3657-3662, 2002.
21. Miao, H. Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., and Klagsbrun, M. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility. Functional competition of collapsin-1 and vascular endothelial growth factor-165. J. Cell Biol., 146: 233-242, 1999.
22. Serini, G., Valdembri, D., Zanivan, S., Morterra, G., Burkhardt, C., Caccavari, F., Zammataro, L., Primo, L., Tamagnone, L., Logan, M., Tessier-Lavigne, M., Taniguchi, M., Puschel, A. W., and Bussolino, F. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature (Lond.), 424: 391-397, 2003.
23. Bates, D., Taylor, G. I., Minichiello, J., Farlie, P., Cichowitz, A., Watson, N., Klagsbrun, M., Mamluk, R., and Newgreen, D. F. Neurovascular congruence results from a shared patterning mechanism that utilizes Semaphorin3A and Neuropilin-1. Dev. Biol., 255: 77-98, 2003.
24. Shirvan, A., Ziv, I., Fleminger, G., Shina, R., He, Z. G., Brudo, I., Melamed, E., and Barzilai, A. Semaphorins as mediators of neuronal apoptosis. J. Neurochem., 73: 961-971, 1999.
25. Behar, O., Golden, J. A., Mashimo, H., Schoen, F. J., and Fishman, M. C. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature (Lond.), 383: 525-528, 1996.
26. Sahay, A., Molliver, M. E., Ginty, D. D., and Kolodkin, A. L. Semaphorin 3F is critical for development of limbic system circuitry and is required in neurons for selective CNS axon guidance events. J. Neurosci., 23: 6671-6680, 2003.
27. Nasarre, P., Constantin, B., Rouhaud, L., Harnois, T., Raymond, G., Drabkin, H. A., Bourmeyster, N., and Roche, J. Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia, 5: 83-92, 2003.
28. Enciso, J. M., Gratzinger, D., Camenisch, T. D., Canosa, S., Pinter, E., and Madri, J. A. Elevated glucose inhibits VEGF-A-mediated endocardial cushion formation: modulation by PECAM-1 and MMP-2. J. Cell Biol., 160: 605-615, 2003.
29. Lange, T., Gutman-Raviv, N., Baruch, L., Machluf, M., and Neufeld, G. VEGF162: a new heparin binding VEGF splice form that is expressed in transformed human cells. J. Biol. Chem., 278: 17164-17169, 2003.
30. Peretz, D., Gitay-Goren, H., Safran, M., Kimmel, N., Gospodarowicz, D., and Neufeld, G. Glycosylation of vascular endothelial growth factor is not required for its mitogenic activity. Biochem. Biophys. Res. Commun., 182: 1340-1347, 1992.
31. Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried, N. T., Dunn, I. F., Abe, T., Carroll, R. S., and Black, P. M. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotechnol., 19: 35-39, 2001.
32. Cohen, T., Gitay-Goren, H., Neufeld, G., and Levi, B-Z. High levels of biologically active vascular endothelial growth factor (VEGF) are produced by the baculovirus expression system. Growth Factors, 7: 131-138, 1992.
33. Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H. K., Reaman, G. H., and Tosato, G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 182: 155-162, 1995.
34. Sabo, E., Boltenko, A., Sova, Y., Stein, A., Kleinhaus, S., and Resnick, M. B. Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin. Cancer Res., 7: 533-537, 2001.
35. Neufeld, G., and Gospodarowicz, D. The identification and partial characterization of the fibroblast growth factor receptor of baby hamster kidney cells. J. Biol. Chem., 260: 13860-13868, 1985.
36. Migdal, M., Soker, S., Yarden, Y., and Neufeld, G. Activation of a transfected FGFR-1 receptor in madin-darby epithelial cells results in a reversible loss of epithelial properties. J. Cell. Physiol., 162: 266-276, 1995.
37. Nakamura, F., Kalb, R. G., and Strittmatter, S. M. Molecular basis of semaphorin-mediated axon guidance. J. Neurobiol., 44: 219-229, 2000.
38. Cross, M. J., and Claesson-Welsh, L. FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci., 22: 201-207, 2001.
39. Giuliani, R., Bastaki, M., Coltrini, D., and Presta, M. Role of endothelial cell extracellular signal-regulated kinase 1/2 in urokinase-type plasminogen activator up-regulation and in vitro angiogenesis by fibroblast growth factor-2. J. Cell Sci., 112: 2597-2606, 1999.
40. Meadows, K. N., Bryant, P., and Pumiglia, K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J. Biol. Chem., 276: 49289-49298, 2001.
41. Tille, J. C., Wood, J., Mandriota, S. J., Schnell, C., Ferrari, S., Mestan, J., Zhu, Z., Witte, L., and Pepper, M. S. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J. Pharmacol. Exp. Ther., 299: 1073-1085, 2001.
42. Kendall, R. L., and Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA, 90: 10705-10709, 1993.
43. Plunkett, M. L., and Hailey, J. A. An in vivo quantitative angiogenesis model using tumor cells entrapped in alginate. Lab. Investig., 62: 510-517, 1990.
44. Poltorak, Z., Cohen, T., Sivan, R., Kandelis, Y., Spira, G., Vlodavsky, I., Keshet, E., and Neufeld, G. VEGF145: a secreted VEGF form that binds to extracellular matrix. J. Biol. Chem., 272: 7151-7158, 1997.
45. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-74, 1977.
46. Cheng, J. D., Dunbrack, R. L., Jr., Valianou, M., Rogatko, A., Alpaugh, R. K., and Weiner, L. M. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res., 62: 4767-4772, 2002.
47. Hata, Y., Rook, S. L., and Aiello, L. P. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes, 48: 1145-1155, 1999.
48. Gehlbach, P., Demetriades, A. M., Yamamoto, S., Deering, T., Xiao, W. H., Duh, E. J., Yang, H. S., Lai, H., Kovesdi, I., Carrion, M., Wei, L., and Campochiaro, P. A. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum. Gene Ther., 14: 129-141, 2003.
49. Folkman, J. What is the evidence that tumors are angiogenesis dependent. J. Natl. Cancer Inst. (Bethesda), 82: 4-7, 1990.
50. Giger, R. J., Cloutier, J. F., Sahay, A., Prinjha, R. K., Levengood, D. V., Moore, S. E., Pickering, S., Simmons, D., Rastan, S., Walsh, F. S., Kolodkin, A. L., Ginty, D. D., and Geppert, M. Neuropilin-2 is required in vivo for selective axon guidance responses to secreted semaphorins. Neuron, 25: 29-41, 2000.
51. Chen, H., Bagri, A., Zupicich, J. A., Zou, Y., Stoeckli, E., Pleasure, S. J., Lowenstein, D. H., Skarnes, W. C., Chedotal, A., and Tessier-Lavigne, M. Neuropilin-2 regulates the development of selective cranial and sensory nerves and hippocampal mossy fiber projections. Neuron, 25: 43-56, 2000.
52. Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., Scholz, D., Acker, T., Dipalma, T., Dewerchin, M., Noel, A., Stalmans, I., Barra, A., Blacher, S., Vandendriessche, T., Ponten, A., Eriksson, U., Plate, K. H., Foidart, J. M., Schaper, W., Charnock-Jones, D. S., Hicklin, D. J., Herbert, J. M., Collen, D., and Persico, M. G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med., 7: 575-583, 2001.